Fulminant hepatic failure: Summary of a workshop

Hepatology

Volumn 21, Issue 1, 1995, Pages 240-252

  Hoofnagle, Jay H ^a   Carithers Jr , Robert L ^b   Shapiro, Craig ^c   Ascher, Nancy ^d  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BILIRUBIN; PARACETAMOL; PROSTAGLANDIN; PROSTAGLANDIN E1; TACROLIMUS;

BRAIN EDEMA; CONFERENCE PAPER; DRUG INDUCED DISEASE; HEMODYNAMIC MONITORING; HEPATITIS; HUMAN; LIVER FAILURE; LIVER PROTECTION; LIVER TOXICITY; LIVER TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS; UNITED STATES; VIRUS INFECTION;

ALPROSTADIL; CELL TRANSPLANTATION; CEREBROSPINAL FLUID PRESSURE; HEPATIC ENCEPHALOPATHY; HUMAN; INCIDENCE; LIVER; LIVER TRANSPLANTATION; PROGNOSIS; TRANSPLANTATION, HETEROLOGOUS; UNITED STATES;

EID: 0028873005     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1016/0270-9139(95)90434-4     Document Type: Article

References (75)

1. Fulminant hepatic failure
2. Etiology of fulminant hepatic failure: is another virus involved?
3. Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis
4. Syncytial giant-cell hepatitis
5. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis
6. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis
7. Association of a precore genomic variant of hepatitis B virus with fulminant hepatitis
8. Sequences of hepatitis B virus DNA in the serum and liver of patients with acute benign and fulminant hepatitis
9. Hepatitis B virus and apparent non-A, non-B hepatitis
10. Summary of notifiable diseases, United States, 1991
11. The changing epidemiology of hepatitis B in the United States: need for alternative vaccination strategies
12. The natural history of community-acquired hepatitis C in the United States
13. Multiple cause of death data
14. National hospital discharge survey
15. Liver transplantation in the United States: 1988 to 1990
16. The NIDDK Liver Transplantation Database
17. The fulminant hepatic failure surveillance study: brief review of the effects of presumed etiology and age on survival
18. Relation of alpha-fetoprotein in acute hepatitis to severity and prognosis
19. Multivariate analysis of prognostic factors in fulminant hepatitis B
20. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure
21. Early indicators of prognosis in fulminant hepatic failure
22. Determination of the ketone body ratio in fulminant hepatic failure
23. Prospective study of bacterial infection in acute liver failure: an analysis of 50 patients
24. The prevalence and prognostic significance of spontaneous bacterial peritonitis in severe acute hepatitis with ascites
25. Prospective controlled trial of selective and enteral antimicrobial regimen in fulminant liver failure
26. Selective intestinal decontamination in the prevention of bacterial infection in patients with acute liver failure
27. Portal hypertension in acute liver failure
28. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial
29. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure
30. Ammonia and related amino acids in the pathogenesis of brain edema in acute ischemic liver failure in rats
31. Inhibition of brain glutamine accumulation prevents cerebral edema in hyperammonemic rats
32. Clinical monitoring of intracranial pressure in fulminant hepatic failure
33. Controlled trial of dexamethasone and mannitol for the cerebral oedema of fulminant hepatic failure
34. Management of acute elevation of intracranial pressure during hepatic transplantation
35. Complications of intracranial pressure monitoring in fulminant hepatic failure
36. Liver transplantation for fulminant hepatic failure: the role of intracranial pressure monitoring
37. Liver transplantation for fulminant hepatic failure
38. Advantages of intracranial pressure monitoring in patients with fulminant liver failure
39. Regeneration of the native liver after heterotopic liver transplantation for fulminant hepatic failure
40. Heterotopic liver transplantation for fulminant hepatic failure-a bridge to recovery
41. Auxiliary partial orthotopic liver transplantation (APOLT) for fulminant hepatic failure first successful case report
42. Orthotopic auxiliary liver transplantation the treatment of choice for acute liver failure?
43. Artificial liver: state of the art
44. Fulminant hepatic failure and the need for artificial liver support
45. Reversal of fulminant hepatic failure using an extracorporeal liver assist device
46. Recovery from syncytial giant-cell (SGCH) hepatitis following treatment with an extra-corporeal liver assist device (ELAD)
47. Development of a bioartificial liver: properties and function of a hollow-fiber module inoculated with liver cells
48. Control of cerebral oedema by total hepatectomy and extracorporeal liver support in fulminant hepatic failure
49. Human liver cell transplantation: prolonged function in athymic rats
50. Transplantation of microcarrier-attached human hepatocytes into Gunn rats
51. Replacement of liver function in rat by transplantation of microcarrier-attache hepatocytes
52. Transplantation of microencapsulated hepatocytes into analbuminemic rats
53. Long-term improvement of hypercholesterolemia after ex vivo gene therapy in LDLR-deficient rabbits
54. Frontiers in gene therapy: LDL receptor replacement for hypercholesterolemia
55. Transplantation of microcarrierattached hepatocytes into 90% partially hepatectomized rats
56. Interferon system in acute viral hepatitis
57. Recombinant alpha-2c interferon therapy in fulminant viral hepatitis
58. Recombinant human interferon alfa-2b in the management of acute type B hepatitis
59. Eicosanoids, signal molecules of liver cells
60. 2) and a prostaglandin analogue BW 245C on galactosamine-induced hepatic necrosis
61. 2 prevents the development of fulminant hepatitis and blocks the induction of monocyte/macrophage procoagulant activity after murine hepatitis virus strain 3 infection
62. Biochemical and clinical response of fulminant viral hepatitis to administration of prostaglandin E: a preliminary report
63. Does prostaglandin E1 (PGE1) prevent further aggravation in severe, or early fulminant hepatitis?
64. 2 in the treatment of fulminant hepatic failure
65. Successful application of extracorporeal liver perfusion for the treatment of fulminant hepatitis failure: a technology whose time has come
66. Extracorporeal porcine liver perfusion as a successful bridge to orthotopic liver transplantation (OLT)
67. Brief report: treatment of hepatic failure with ex vivo pig-liver perfusion followed by liver transplantation
68. Renal hetero-transplantation in man
69. Baboon to human cardiac xenotransplantation in a neonate
70. Hamster to rat heart and liver xenotransplantation with FK506 plus anti-proliferative drugs
71. Control of cerebral edema by total hepatectomy and extracorporeal liver support in fulminant hepatic failure
72. Experience in the treatment of hepatic failure by intermittent liver hemo-perfusions
73. Baboon-to-human liver transplantation
74. Orthotopic liver transplantation for patients with hepatitis B virus related liver disease
75. Xenotransplantation: baboons as potential liver donors?